AlphaQuest LLC Takes $39,000 Position in Certara, Inc. $CERT

AlphaQuest LLC purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 3,918 shares of the company’s stock, valued at approximately $39,000.

A number of other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN increased its stake in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. First Trust Advisors LP bought a new position in Certara in the fourth quarter valued at $140,000. Price T Rowe Associates Inc. MD increased its stake in Certara by 6.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,494 shares of the company’s stock valued at $762,000 after acquiring an additional 4,229 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock valued at $253,000 after acquiring an additional 823 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Certara by 14.0% in the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company’s stock valued at $9,340,000 after acquiring an additional 108,038 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CERT shares. KeyCorp reduced their target price on Certara from $18.00 to $15.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Morgan Stanley started coverage on Certara in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price on the stock. UBS Group reduced their target price on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Barclays raised Certara from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Certara Stock Performance

Certara stock opened at $10.58 on Friday. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.70 billion, a PE ratio of 211.64 and a beta of 1.43. The firm has a fifty day simple moving average of $10.81 and a two-hundred day simple moving average of $11.39. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $15.69.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.The business’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.07 earnings per share. Research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.